Categories Uncategorized

Smartphones Can Now Accurately Test Sperm Count

Low sperm count is one of the primary causes of male infertility, according to the World Health Organization, and the issue has been globally neglected for a very long time. However, researchers are developing smartphone apps that can efficiently detect low sperm count in men.

The Invention of a Rapid Infertility Diagnostic Tool

Researchers from Harvard University have successfully invented a rapid infertility diagnostic tool attached to the smartphone. The attachment itself is compatible with the app created to count the sperm numbers and measure its motility. However, while the researchers from Harvard were not the first team to develop an at-home fertility test for men, they are the first to resolve sperm count in addition to flexibility successfully.

The Simplicity of the Process

The process of testing your sperm count has been made simpler. It now only entails taking small semen and loading it in a disposable microchip. The chip is then placed into a mobile phone attachment through a slot. Eventually, the attachment will turn your phone’s camera into a microscope, which will examine the specimen.

When the sample has been completely loaded and the app starts running, the user will be allowed to see a video of that sample. Additionally, the recording button can be pressed, and the app will subsequently analyze the video, identify sperm cells, and track their movements.

Tracking the Process

Researchers had to make a side-by-side analog of the smartphone sperm tracker with modern lab equipment, and the process involved analyzing over 350 semen samples of both fertile and infertile males. The smartphone app recognition process recorded a 98% system accuracy. The tracking process also involved whether untrained persons with non-scientific knowledge could safely and successfully use the app. According to the researchers, it was confirmed that both trained and the untrained could operate the at-home test app without any hardship.

Developing a Compatible App for iPhone

The cell phone app has only been designed to work with android devices, limiting iPhone users. However, the team is also creating a version that will be compatible with iPhones. The machine will be availed for a lower price for affordability, especially for people in developing nations.

Furthermore, this device is expected to test for male infertility and to help men who have recently undergone a vasectomy. After a vasectomy, scientists always encourage men to undertake a sperm count test to determine if the process was successful.

For the complete production of these apps, manufacturers are waiting for approval from the FDA to begin mass production. If the process is approved, fertility tests for men at home will be easy as an at-home pregnancy test for women.

This development is likely to be welcomed by companies like LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) who are themselves involved in coming up with novel solutions to health problems afflicting millions around the world.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…

3 days ago

Oncolytic Virus Therapy is Set to Transform Cancer Care

Enormous resources are being channeled into studying different ways to support the immune system in its fight…

3 days ago

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…

3 days ago

Study Finds That Marijuana Legalization Lowers Crime Rates

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…

4 days ago

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…

5 days ago

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…

5 days ago